At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Long-term Follow-up Study of Botulinum Toxin Type A in Patients With Overactive Bladder as a Result of Spinal Injury or Multiple Sclerosis
In Brief
A Phase 3 clinical trial evaluating Botulinum Toxin Type A 300U and Botulinum Toxin Type A 200U for Overactive Bladder. Completed, enrolled 397 participants across 22 sites in 22 countries.
Detailed Summary
The purpose of this study is to assess the long-term safety and effectiveness of botulinum toxin type A on patients with overactive bladder as a result of spinal cord injury or multiple sclerosis. This is a follow-up study to two Allergan sponsored studies (NCT00311376 and NCT00461292).
Study Details
Timeline
Interventions
Botulinum toxin Type A 300U injections into the detrusor \> 12 weeks as needed for up to 3 years.
Botulinum toxin Type A 200U injections into the detrusor \> 12 weeks as needed for up to 3 years.